

## LES GCO à l'ESMO 2021

---

*GCO-001 NIPINEC : Premier essai clinique multi-organes dans les carcinomes neuro-endocrines des Groupes Coopérateurs en Oncologie présenté*

---

### ORAL PRESENTATION

Nivolumab (nivo) ± Ipilimumab (ipi) in pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (GCO-001 NIPINEC)

**Thomas Walter - LBA41 S**

[Voir le communiqué](#)

---

### ARCAGY-GINECO

*Association de Recherche sur les Cancers dont Gynécologiques Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du sein*

---

### ORAL PRESENTATION

*Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial*

**Eric Pujade-Lauraine – LBA33**

### POSTER

*Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study*

**Alexandra Leary - Abstract #727P**

*Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study*

**Gilles Freyer - Abstract #733P**

*COLIBRI trial (GINECO-CE108b): A multicenter, window study evaluating immune impact and safety of nivolumab in combination with ipilimumab before initial radio-chemotherapy (RTCT) treatment for locally advanced cervix cancer*

**Isabelle Ray-Coquard– Abstract #819TiP**

*Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIg meta-analysis group*

**Susana Banerjee– Abstract #815TiP**

*Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIg meta-analysis group*

**Pauline Corbaux– Abstract #751P**

*Immune features of high-grade ovarian cancer associated with exceptional disease-free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study*

**Louis Mourani– Abstract #741P**

*Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial*

**Maria-Pilar Barretina-Ginesta– Abstract #738P**

*GREAT: A multicentric cohort of advanced ovarian cancer (AOC) treated in real life with prospective collection of clinical data, tumor sample, and biomarkers (tBRCA, HRD) including genomic putative theranostic markers: A GINECO study*

**Thibaut de la Motte Rouge– Abstract #821TiP**

*Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged  $\geq 65$  years (y) from the PAOLA 1/ENGOT-ov25 first-line trial*

**Renaud Sabatier– Abstract #739P**

---

**FFCD**

*Fédération Francophone de la Cancérologie Digestive*

---

**POSTER**

PRODIGE 34 : Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial.

**MINI ORAL**

PETACC8/N0147/TOSCA : Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients – a pooled analysis of 3 adjuvant trials

---

**IFCT**

*Intergroupe Francophone de cancérologie thoracique*

---

**ORAL PRESENTATION**

Nivolumab (nivo) ± Ipilimumab (ipi) in pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (GCO-001 NIPINEC)

**Thomas Walter - LBA41 S**

**ORAL PRESENTATION**

An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: characterisation of PORT efficacy in Lung ART (IFCT-0503, UK NCRI, SAKK)

**Cécile Le Pechoux – Abstract #11700**

**MINI ORAL SESSION**

Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.

**Marie Wislez – Abstract #1151MO**